AC Immune (NASDAQ:ACIU - Get Free Report) is scheduled to announce its earnings results on Friday, April 26th.
AC Immune (NASDAQ:ACIU - Get Free Report) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $16.71 million during the quarter, compared to the consensus estimate of $16.36 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
AC Immune Price Performance
AC Immune stock traded down $0.08 during trading hours on Thursday, hitting $2.29. The company had a trading volume of 109,028 shares, compared to its average volume of 170,502. The firm has a market cap of $226.48 million, a PE ratio of -3.38 and a beta of 1.00. AC Immune has a one year low of $1.78 and a one year high of $5.14. The firm has a 50-day moving average of $3.12 and a 200 day moving average of $3.34.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of AC Immune in a research report on Friday, March 15th.
Get Our Latest Report on ACIU
AC Immune Company Profile
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Stories
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
